The use of estrogen in the treatment of Parkinson's disease.
Tsang
K L
KL
Division of Neurology, University Department of Medicine, Queen Mary Hospital, Hong Kong.
Jiang
H
H
Ramsden
D B
DB
Ho
S L
SL
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D003342:Corpus Striatum / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D008597:Menstrual Cycle; D008780:Methyltransferases / Q000378:metabolism; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D012727:Sex Characteristics; D013378:Substantia Nigra / Q000187:drug effects
D000978:Antiparkinson Agents; D004967:Estrogens; D018696:Neuroprotective Agents; D008780:Methyltransferases; C019608:caffeate O-methyltransferase; D004298:Dopamine